BridgeBio Oncology Therapeutics and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines Press Release: March 3, 2025 Read More
Go back to Press Page
